Company research

Explore company profiles, quarterly results, announcements and ownership disclosures.

Loading the company view…

Venmax Drugs and Pharmaceuticals Ltd (VENMAX) — Stock Analysis

Venmax Drugs and Pharmaceuticals Ltd (NSE: VENMAX), ISIN INE154G01022 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.

VENMAX last traded at ₹15.96 (-0.06%), with a 52-week range of ₹12.71 to ₹31.49 (as of 23 Sep 2026).

Shareholding as of Dec 2025: promoters 15.14%, FIIs 0.00%, DIIs 0.00%, mutual funds 0.00%.

EquiSense Score (ECS): 56/100.

Data sourced from NSE and BSE filings. Educational — not investment advice.